96 related articles for article (PubMed ID: 35279106)
1. Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
Garg G; Vangveravong S; Zeng C; Collins L; Hornick M; Hashim Y; Piwnica-Worms D; Powell MA; Mutch DG; Mach RH; Hawkins WG; Spitzer D
Mol Cancer; 2014 Mar; 13():50. PubMed ID: 24602489
[TBL] [Abstract][Full Text] [Related]
2. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Noriega-Rivera R; Rivera-Serrano M; Rabelo-Fernandez RJ; Pérez-Santiago J; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887085
[TBL] [Abstract][Full Text] [Related]
4. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms.
Zhang X; Liao X; Wang M; Liu J; Han J; An D; Zheng T; Wang X; Cheng H; Liu P
Cancer Sci; 2024 Apr; 115(4):1170-1183. PubMed ID: 38287874
[TBL] [Abstract][Full Text] [Related]
6. BSV163/DOPE-mediated TRAIL gene transfection acts synergistically with chemotherapy against cisplatin-resistant ovarian cancer.
Nguyen QM; Dupré PF; Berchel M; Ghanem R; Jaffrès PA; d'Arbonneau F; Montier T
Chem Biol Drug Des; 2024 Jan; 103(1):e14357. PubMed ID: 37731182
[TBL] [Abstract][Full Text] [Related]
7. Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.
Alexander ET; Minton AR; Peters MC; van Ryn J; Gilmour SK
Oncotarget; 2016 Dec; 7(51):85291-85305. PubMed ID: 27852034
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.
Russell S; Duquette M; Liu J; Drapkin R; Lawler J; Petrik J
FASEB J; 2015 Feb; 29(2):576-88. PubMed ID: 25395453
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2: hope in cases of cisplatin-resistant tumours.
Bernsen MR; Van Der Velden AW; Everse LA; Dullens HF; Den Otter W; Heintz AP
Cancer Immunol Immunother; 1998 Mar; 46(1):41-7. PubMed ID: 9520291
[TBL] [Abstract][Full Text] [Related]
10. A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance.
Suzuki T; Conant A; Jung Y; Bax R; Antonissen A; Chen W; Yu G; Ioffe YJ; Wang C; Unternaehrer JJ
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612653
[TBL] [Abstract][Full Text] [Related]
11. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.
Parashar D; Geethadevi A; McAllister D; Ebben J; Peterson FC; Jensen DR; Bishop E; Pradeep S; Volkman BF; Dwinell MB; Chaluvally-Raghavan P; James MA
NPJ Precis Oncol; 2021 Mar; 5(1):16. PubMed ID: 33654182
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Platinum-Resistance Ovarian Cancer Patients.
Vizzielli G; Giudice MT; Fagotti A; Scambia G
Ann Surg Oncol; 2024 Feb; 31(2):1217-1218. PubMed ID: 38071702
[No Abstract] [Full Text] [Related]
13. Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer.
Hopkins D; Sanchez H; Berwin B; Wilkinson-Ryan I
Transl Oncol; 2021 Dec; 14(12):101217. PubMed ID: 34530192
[TBL] [Abstract][Full Text] [Related]
14. RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors.
Dreaden EC; Kong YW; Quadir MA; Correa S; Suárez-López L; Barberio AE; Hwang MK; Shi AC; Oberlton B; Gallagher PN; Shopsowitz KE; Elias KM; Yaffe MB; Hammond PT
Bioeng Transl Med; 2018 Jan; 3(1):26-36. PubMed ID: 29376131
[TBL] [Abstract][Full Text] [Related]
15. Immunological parameters as a new lead in the diagnosis of ovarian cancer.
Baert T; Timmerman D; Vergote I; Coosemans A
Facts Views Vis Obgyn; 2015; 7(1):67-72. PubMed ID: 25897373
[TBL] [Abstract][Full Text] [Related]
16. The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
Hagi T; Vangveravong S; Takchi R; Gong Q; Goedegebuure SP; Tiriac H; Van Tine BA; Powell MA; Hawkins WG; Spitzer D
Sci Rep; 2024 Mar; 14(1):6373. PubMed ID: 38493257
[TBL] [Abstract][Full Text] [Related]
17. Development of Fluorescent 4-[4-(3
Abatematteo FS; Majellaro M; Montsch B; Prieto-Díaz R; Niso M; Contino M; Stefanachi A; Riganti C; Mangiatordi GF; Delre P; Heffeter P; Sotelo E; Abate C
J Med Chem; 2023 Mar; 66(6):3798-3817. PubMed ID: 36919956
[TBL] [Abstract][Full Text] [Related]
18. The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
Binder PS; Hashim YM; Cripe J; Buchanan T; Zamorano A; Vangveravong S; Mutch DG; Hawkins WG; Powell MA; Spitzer D
BMC Cancer; 2022 Mar; 22(1):263. PubMed ID: 35279106
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
